CRISPR Gene Therapy for Sickle Cell Disease

How Does CRISPR Gene Therapy Treat Sickle Cell Disease?

Sickle cell disease is caused by a single-letter mutation in the HBB gene that produces abnormal hemoglobin, causing red blood cells to deform into rigid sickle shapes that block blood vessels and trigger painful crises. CRISPR therapy, branded as Casgevy (exagamglogene autotemcel), takes a different approach than directly correcting the mutation. The treatment edits the BCL11A gene in a patient's hematopoietic stem cells, switching off a genetic brake that normally silences fetal hemoglobin production after birth.

The reactivated fetal hemoglobin compensates for the defective adult hemoglobin, dramatically reducing pain crises and hospitalizations. The process requires harvesting a patient's stem cells, editing them in a laboratory using CRISPR-Cas9, and reinfusing them after chemotherapy conditioning. Clinical trial data showed the vast majority of treated patients remained free of severe vaso-occlusive crises for at least one year after treatment, a remarkable result for a previously incurable genetic disease.

What Is the Future of CRISPR Therapies Beyond Sickle Cell?

Dr. Jennifer Doudna, who shared the 2020 Nobel Prize in Chemistry for co-discovering CRISPR-Cas9, has emphasized that current ex vivo gene therapies, while transformative, remain expensive, complex, and inaccessible to most of the world's sickle cell patients, particularly in sub-Saharan Africa where the disease burden is highest. The next frontier involves in vivo CRISPR therapies that can be delivered directly to the body via injection, eliminating the need for stem cell harvesting and chemotherapy conditioning.

Beyond sickle cell, CRISPR-based platforms are advancing through clinical trials for transthyretin amyloidosis, hereditary angioedema, familial hypercholesterolemia, and various cancers. Newer technologies including base editing and prime editing offer more precise modifications without creating double-strand DNA breaks, potentially reducing off-target effects. The Innovative Genomics Institute, founded by Doudna, is also working on affordability frameworks to ensure these breakthroughs reach low-income and middle-income countries where genetic diseases like sickle cell remain a major public health burden.

Who Is Eligible for CRISPR Gene Therapy and What Are the Risks?

The FDA approved Casgevy for patients aged 12 and older with sickle cell disease who experience recurrent vaso-occlusive crises. Eligibility requires a thorough evaluation at specialized treatment centers, as the procedure involves myeloablative conditioning with busulfan chemotherapy to make room for the edited stem cells. This conditioning carries risks including infertility, infections, and potential long-term effects from cytotoxic exposure.

Cost remains a major barrier, with list prices reported around $2.2 million per patient in the United States, though insurance coverage and federal programs are evolving. Long-term safety data continues to accumulate, with researchers monitoring for any unintended genetic consequences of CRISPR editing. For patients without access to bone marrow transplant donors, this therapy represents a potentially curative option that did not exist just a few years ago.